These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16355014)

  • 1. Importance and management of dyslipidemia in the metabolic syndrome.
    Menuet R; Lavie CJ; Milani RV
    Am J Med Sci; 2005 Dec; 330(6):295-302. PubMed ID: 16355014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of the metabolic syndrome.
    Hafidh S; Senkottaiyan N; Villarreal D; Alpert MA
    Am J Med Sci; 2005 Dec; 330(6):343-51. PubMed ID: 16355020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of hypertriglyceridemia.
    Oh RC; Lanier JB
    Am Fam Physician; 2007 May; 75(9):1365-71. PubMed ID: 17508532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of dyslipidemia in the metabolic syndrome.
    Tan KC
    Cardiovasc Hematol Disord Drug Targets; 2007 Jun; 7(2):99-108. PubMed ID: 17584044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypertriglyceridemia and cardiovascular risk reduction.
    Jacobson TA; Miller M; Schaefer EJ
    Clin Ther; 2007 May; 29(5):763-777. PubMed ID: 17697898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia.
    Wohl DA; Tien HC; Busby M; Cunningham C; Macintosh B; Napravnik S; Danan E; Donovan K; Hossenipour M; Simpson RJ
    Clin Infect Dis; 2005 Nov; 41(10):1498-504. PubMed ID: 16231263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dyslipidemia in visceral obesity: mechanisms, implications, and therapy.
    Chan DC; Barrett HP; Watts GF
    Am J Cardiovasc Drugs; 2004; 4(4):227-46. PubMed ID: 15285698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.
    Tenenbaum A; Fisman EZ; Motro M; Adler Y
    Cardiovasc Diabetol; 2006 Sep; 5():20. PubMed ID: 17002798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.
    Ascaso J; Gonzalez Santos P; Hernandez Mijares A; Mangas Rojas A; Masana L; Millan J; Pallardo LF; Pedro-Botet J; Perez Jimenez F; Pintó X; Plaza I; Rubiés J; Zúñiga M
    Am J Cardiovasc Drugs; 2007; 7(1):39-58. PubMed ID: 17355165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypertriglyceridemia: management of atherogenic dyslipidemia.
    Bersot T; Haffner S; Harris WS; Kellick KA; Morris CM
    J Fam Pract; 2006 Jul; 55(7):S1-8. PubMed ID: 16822443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging approaches for the treatment of hypertriglyceridemia.
    Rizzo M; Perez-Martinez P; Nikolic D; Montalto G; Lopez-Miranda J
    Expert Opin Pharmacother; 2013 Oct; 14(14):1869-73. PubMed ID: 24011268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of hypertriglyceridemia. Current aspects].
    Malaguarnera M; Giugno I; Ruello P; Vinci E; Panebianco MP; Motta M
    Recenti Prog Med; 2000; 91(7-8):379-87. PubMed ID: 10932925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omega-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia.
    Pirillo A; Catapano AL
    Atheroscler Suppl; 2013 Aug; 14(2):237-42. PubMed ID: 23958479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management issues in the metabolic syndrome.
    Deedwania PC; Gupta R
    J Assoc Physicians India; 2006 Oct; 54():797-810. PubMed ID: 17214277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A physician's guide for the management of hypertriglyceridemia: the etiology of hypertriglyceridemia determines treatment strategy.
    Klop B; Wouter Jukema J; Rabelink TJ; Castro Cabezas M
    Panminerva Med; 2012 Jun; 54(2):91-103. PubMed ID: 22525564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atherogenic Dyslipidemia and Residual Vascular Risk in Practice of Family Doctor.
    Alibasic E; Ramic E; Bajraktarevic A; Ljuca F; Batic-Mujanovic O; Zildzic M
    Med Arch; 2015 Oct; 69(5):339-41. PubMed ID: 26622090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.